David Sans, FAARM, PhD, MBA
New York City Metropolitan Area
8K followers
500+ connections
About
Dr. David Sans performs investment banking services utilizing the Financial Entrepreneurs…
Activity
-
I am excited to take on an additional role as the new Head of Business Development & Licensing / Open Innovation (BDL/OI) within the Bayer |…
I am excited to take on an additional role as the new Head of Business Development & Licensing / Open Innovation (BDL/OI) within the Bayer |…
Liked by David Sans, FAARM, PhD, MBA
-
Sichenzia Ross Ference Carmel LLP Represents EF Hutton LLC in a $2 Million Common Stock Offering of NRx Pharmaceuticals, Inc. NRx Pharmaceuticals…
Sichenzia Ross Ference Carmel LLP Represents EF Hutton LLC in a $2 Million Common Stock Offering of NRx Pharmaceuticals, Inc. NRx Pharmaceuticals…
Liked by David Sans, FAARM, PhD, MBA
-
I'm delighted to share news of this new AI-focused drug discovery company, Xaira, built on foundational technology from David Baker and led by Marc…
I'm delighted to share news of this new AI-focused drug discovery company, Xaira, built on foundational technology from David Baker and led by Marc…
Liked by David Sans, FAARM, PhD, MBA
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
-
-
-
-
Activities and Societies: Joined Program with IQS Institut Quimic de Sarria in Barcelona and Novartis AG in Basel
-
-
-
-
-
-
Languages
-
Catalan
-
-
English
-
-
German
-
-
French
-
More activity by David
-
EF Hutton’s CEO, Joseph T. Rallo, and President, David W. Boral, met with Nicole DiSturco from St. Jude Children's Research Hospital - ALSAC…
EF Hutton’s CEO, Joseph T. Rallo, and President, David W. Boral, met with Nicole DiSturco from St. Jude Children's Research Hospital - ALSAC…
Liked by David Sans, FAARM, PhD, MBA
-
The FDA is taking a significant step forward to accelerate the development of novel drug and biological products for #rarediseases. The START program…
The FDA is taking a significant step forward to accelerate the development of novel drug and biological products for #rarediseases. The START program…
Liked by David Sans, FAARM, PhD, MBA
-
Check out our most recent transaction with Mainz Biomed! Press Release: https://bit.ly/49AiWxk Michael Sands Jason Sands Adam Sands Ryan Konik…
Check out our most recent transaction with Mainz Biomed! Press Release: https://bit.ly/49AiWxk Michael Sands Jason Sands Adam Sands Ryan Konik…
Liked by David Sans, FAARM, PhD, MBA
-
Leadership is not about size, it is about Courage - amazing.
Leadership is not about size, it is about Courage - amazing.
Shared by David Sans, FAARM, PhD, MBA
-
Thank you to California Institute for Regenerative Medicine (CIRM) and Lila Collins for meeting with the Calidi Biotherapeutics Team in San Diego…
Thank you to California Institute for Regenerative Medicine (CIRM) and Lila Collins for meeting with the Calidi Biotherapeutics Team in San Diego…
Liked by David Sans, FAARM, PhD, MBA
-
Amyloid antibodies have been investigated in early-stage Alzheimer’s disease, and their potential application to Down syndrome is an exciting avenue…
Amyloid antibodies have been investigated in early-stage Alzheimer’s disease, and their potential application to Down syndrome is an exciting avenue…
Liked by David Sans, FAARM, PhD, MBA
-
In the US, the number of people alive aged 65 or older increased from 4.9 million (4.7% of the total U.S. population) in 1920 to 55.8 million (16.8%)…
In the US, the number of people alive aged 65 or older increased from 4.9 million (4.7% of the total U.S. population) in 1920 to 55.8 million (16.8%)…
Liked by David Sans, FAARM, PhD, MBA
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More